Johnson & Johnson Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 362 Posts
1 2 3 ... 23
The 10 Best Dividend Kings For Long-Term Total Returns
Article By: SureDividend Sunday, May 27, 2018 12:42 PM EDT
Dividend Aristocrats are a great source of dividend growth, but there is a smaller group of stocks with a longer history of dividend increases. The Dividend Kings are a group of just 25 stocks, each with 50+ consecutive years of dividend growth.
In this article: ITW, KO, MMM, SJW, CL, JNJ, GPC, PG, DOV, LOW Also: BRK-A, COTY
Dow 30 Stock Roundup: Walmart, Cisco, Home Depot Beat On Earnings
Article By: Swarup Gupta Friday, May 18, 2018 7:42 PM EDT
The Dow snapped a record streak of wins to traverse a turbulent week. Trade-war related concerns continued to weigh on investors with President Trump expressing doubts over the success of upcoming negotiations with China.
In this article: BRK-B, GE, HD, JNJ, JPM, M, PFE, WMT, AAPL, AMGN, CSCO
What Can I Expect To Make If I Invest In Johnson & Johnson Today?
Video By: Chuck Carnevale Tuesday, May 15, 2018 5:35 PM EDT
For much of 2016 and most of 2017, Johnson & Johnson was a little pricey. However, in 2018 Johnson & Johnson’s stock price has been steadily moving towards alignment with intrinsic value.
In this video: JNJ
Pharma Stock Roundup: Mixed Q1 For MRK, PFE, FDA Nod For Kymriah's 2nd Indication
Article By: Zacks Investment Research Friday, May 4, 2018 8:15 PM EDT
First-quarter results of pharma bigwigs like Pfizer, Merck and Allergan stole the limelight this week. Other than that, Novartis gained FDA approval for the second indication of its CAR-T therapy, Kymriah.
In this article: AGN, JNJ, MRK, NVS, PFE, UTHR, ABBV
J&J Tops Q1 Earnings Estimates, Raises Sales Guidance
Article By: Zacks Investment Research Tuesday, April 17, 2018 1:00 PM EDT
J&J’s first-quarter 2018 earnings came in at $2.06 per share.
In this article: JNJ Also: MRK, PFE, ABBV
E J&J's Whisper Number Showing Confidence
Article By: WhisperNumber Monday, April 16, 2018 6:18 PM EDT
Johnson & Johnson (JNJ) is expected to report earnings Tuesday before market open. The whisper number is $2.06, five cents ahead of the analysts' estimates and showing some confidence from the WhisperNumber community.
In this article: JNJ
April 2018 Stock Considerations
Article By: Keith Park Friday, March 30, 2018 7:56 PM EDT
The recent market volatility we have been witnessing the last couple of months has given rise to a plethora of choices for investing that we have not seen in a very, very long time.
In this article: CAH, D, GE, GIS, HCP, JCI, JNJ, KMB, LTC, PPL, SO, VTR, WELL, KHC
Trump Says Federal Suits Coming Against Opioid Manufacturers
Article By: The Fly Friday, March 23, 2018 9:01 PM EDT
In a press conference detailing the $1.3 trillion omnibus government funding bill President Trump announced he would sign, the president mentioned in passing that "we'll be suing" certain drug companies related to the opioid crisis.
In this article: ABC, CAH, JNJ, MCK
Johnson & Johnson: A Dividend King Worth Owning
Article By: SureDividend Friday, March 16, 2018 6:42 PM EDT
Johnson & Johnson is the epitome of a safe investment: Great diversification across industries and geographic markets, a fortress balance sheet, a dividend growth history spanning decades and products that are not cyclical at all.
In this article: JNJ
How Volatility Impacts Retirement Plans
Article By: Doug Carey Tuesday, March 6, 2018 7:45 PM EDT
There really was nowhere to hide during the latest downturn. Very similar to 2008/2009, most assets were correlated and fell together. But also just like in the 2008/2009 downturn, some equities were less volatile than others.
In this article: JNJ, MO, PG, VDC, VIG Also: SPX
Goldman’s Buyback Desk Has Most Active 2 Weeks In History
Article By: The Heisenberg Report Saturday, February 24, 2018 5:02 PM EDT
It’s time for another update on how corporate America intends to spend the windfall from the GOP tax cuts. As far as investors are concerned, the question is how companies are going to spend their tax savings.
In this article: JNJ, MMM, NOC
IBB – Challenging 2016, Recovering 2017 And Resurgence In 2018
Article By: Noah Kiedrowski Tuesday, February 6, 2018 3:12 PM EDT
The Biotechnology cohort has finally notched a 52-week high and has made up much of the lost ground during the pummeling from both sides of the political isle during the 2016 presidential race.
J&J Q4 Earnings Top, Pharma Sales Continue To Improve
Article By: Zacks Investment Research Tuesday, January 23, 2018 11:30 AM EDT
Johnson & Johnson fourth-quarter 2017 earnings came in at $1.74 per share.
In this article: JNJ Also: GSK, MRK, ABBV
Johnson & Johnson (JNJ): A Dividend King That’s Built To Last
Article By: Simply Safe Dividends Sunday, January 21, 2018 12:00 PM EDT
Very few businesses ever come close to growing as large as Johnson & Johnson has become with more than $70 billion in annual revenue.
In this article: JNJ
EC Q4 Earnings Season: Strong Growth, But Weak Quality
Article By: Sheraz Mian Saturday, January 20, 2018 6:24 PM EDT
A lot goes into ‘earnings quality’. But as a general rule, it is reasonable to be wary of a big variance between adjusted and GAAP earnings. Going by this simple rule, you have to question the ‘quality’ of Q4 earnings reports.
In this article: TXN, UAL, VZ, PG, NFLX, SBUX, JNJ, INTC, MMM, GE, HON, IBM
Week In Review: Sinocare Eyes $4 Billion Deal For J&J Diabetes Device Business
Article By: ChinaBio® Today Saturday, January 20, 2018 5:34 PM EDT
Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market.
In this article: JNJ, LLY, CELG, BGNE, MRTX, AMRN
1 to 16 of 362 Posts
1 2 3 ... 23